Sept 24 (Reuters) - CogState Ltd CGS.AX :
* UPDATES ON EISAI AND BIOGEN DECISION TO DISCONTINUE PHASE III CLINICAL STUDIES ON INVESTIGATIONAL ORAL BACE INHIBITOR ELENBECESTAT
* IN ANNOUNCEMENT EISAI STATED DETERMINATION DOES NOT IMPACT PROGRAM OF ANTI-AMYLOID BETA PROTOFIBRIL MONOCLONAL ANTIBODY BAN2401